Solid Biosciences recently completed a big IPO despite disclosing, last-minute, that the FDA had partially suspended a clinical test of its gene therapy for Duchenne muscular dystrophy. Less than two months later, the company has reported a new, and more ominous finding: the FDA has halted testing of the treatment, known as SGT-001, altogether.
Cambridge, MA-based Solid (NASDAQ: SLDB) said late this afternoon that the FDA has placed a study called Ignite DMD, an early-stage test of SGT-001, on clinical hold. Solid said the first patient dosed in the study on Feb. 14 was hospitalized “several days” afterwards when… Read more »
UNDERWRITERS AND PARTNERS